AbbVie News, AbbVie Quote, ABBV Quote

AbbVie (NY:ABBV) Delayed: 167.23 -0.57 (0.34%)

Prev. Close

$167.80

Open

$167.66

52 Wk High

$68.12

52 Wk Low

$50.71

Day High

$169.29

Day Low

$167.23

P/E

36.28

EPS

$4.61

Volume

540,815

Friends, Peers and Foes (?): GMAB, MRK, CERE, BMY, IMGN (more...)

Apr 25, 2024 08:29 AM AbbVie (ABBV): New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary and All Secondary Endpoints
Apr 25, 2024 08:00 AM New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
Apr 25, 2024 05:22 AM AbbVie (ABBV) April weekly 167.50 straddle into quarter results
Apr 23, 2024 08:00 AM Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
Apr 18, 2024 08:31 AM AbbVie (ABBV) Reports Phase 3 SELECT-GCA Study of Upadacitinib Showed Positive Results in Patients With Giant Cell Arteritis
Apr 18, 2024 08:31 AM Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Apr 17, 2024 07:26 AM Q1 earnings buy list: Morgan Stanley picks Nvidia, Amazon and these 10 stocks
Apr 16, 2024 09:56 AM FDA: working with AbbVie (ABBV) to identify, investigate and remove suspected counterfeit Botox products found in the US
Apr 12, 2024 07:31 AM AbbVie (ABBV) Announces Data Supporting Long-Term Safety and Efficacy of Atogepant for Migraine
Apr 12, 2024 07:30 AM AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine

Entities mentioned with ABBV